{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:53:20Z","timestamp":1790402000009,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Lu429\/7-1"],"award-info":[{"award-number":["Lu429\/7-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Lu429\/8-1"],"award-info":[{"award-number":["Lu429\/8-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Lu429\/8-1"],"award-info":[{"award-number":["Lu429\/8-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB922\/Medep project C04"],"award-info":[{"award-number":["SFB922\/Medep project C04"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41375-018-0293-8","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T04:11:14Z","timestamp":1542946274000},"page":"945-956","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation"],"prefix":"10.1038","volume":"33","author":[{"given":"Nadja","family":"Blagitko-Dorfs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8460-0462","authenticated-orcid":false,"given":"Pascal","family":"Schlosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Greve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Baude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2554-3952","authenticated-orcid":false,"given":"Christoph","family":"Plass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"issue":"1","key":"293_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"Mark\u00a0A. Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12\u201327.","journal-title":"Cell"},{"key":"293_CR2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"SB Baylin","year":"2011","unstructured":"Baylin SB, Jones PA. A decade of exploring the cancer epigenome\u2014biological and translational implications. Nat Rev Cancer. 2011;11:726\u201334.","journal-title":"Nat Rev Cancer"},{"key":"293_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nature09165","volume":"466","author":"AK Maunakea","year":"2010","unstructured":"Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D\u2019Souza C, Fouse SD, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010;466:253\u20137.","journal-title":"Nature"},{"key":"293_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/bjc.2011.550","volume":"106","author":"N Shenker","year":"2012","unstructured":"Shenker N, Flanagan JM. Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. Br J Cancer. 2012;106:248\u201353.","journal-title":"Br J Cancer"},{"key":"293_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291\u20139.","journal-title":"Blood"},{"key":"293_CR6","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670\u20137.","journal-title":"J Clin Oncol"},{"key":"293_CR7","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"M L\u00fcbbert","year":"2011","unstructured":"L\u00fcbbert M, Suciu S, Baila L, R\u00fcter BH, Platzbecker U, Giagounidis A, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29:1987\u201396.","journal-title":"J Clin Oncol"},{"key":"293_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/5047","volume":"21","author":"EE Cameron","year":"1999","unstructured":"Cameron EE, Bachman KE, My\u00f6h\u00e4nen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103\u20137.","journal-title":"Nat Genet"},{"key":"293_CR9","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","volume":"32","author":"T Prebet","year":"2014","unstructured":"Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905. J Clin Oncol. 2014;32:1242\u20138.","journal-title":"J Clin Oncol"},{"key":"293_CR10","first-page":"6","volume":"6","author":"SD Gore","year":"2008","unstructured":"Gore SD. New agents for the treatment of AML recent study findings. Clin Adv Hematol Oncol. 2008;6:6\u20138.","journal-title":"Clin Adv Hematol Oncol"},{"key":"293_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.13016","volume":"167","author":"M Kirschbaum","year":"2014","unstructured":"Kirschbaum M, Gojo I, Goldberg SL, Bredeson C, Kujawski LA, Yang A, et al. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Br J Haematol. 2014;167:185\u201393.","journal-title":"Br J Haematol"},{"key":"293_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-07-604512","volume":"127","author":"BJ Wouters","year":"2016","unstructured":"Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. 2016;127:42\u201352.","journal-title":"Blood"},{"key":"293_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.68","volume":"4","author":"P Tan","year":"2014","unstructured":"Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 2014;4:e170.","journal-title":"Blood Cancer J"},{"key":"293_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/leu.2008.397","volume":"23","author":"C Flotho","year":"2009","unstructured":"Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23:1019\u201328.","journal-title":"Leukemia"},{"key":"293_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/sj.leu.2403552","volume":"19","author":"K Schmelz","year":"2005","unstructured":"Schmelz K, Sattler N, Wagner M, L\u00fcbbert M, D\u00f6rken B, Tamm I. Induction of gene expression by 5-Aza-2\u2019-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia. 2005;19:103\u201311.","journal-title":"Leukemia"},{"key":"293_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2014.07.028","volume":"26","author":"X Yang","year":"2014","unstructured":"Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell. 2014;26:577\u201390.","journal-title":"Cancer Cell"},{"key":"293_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2144\/03351md02","volume":"35","author":"J Tost","year":"2003","unstructured":"Tost J, Dunker J, Gut IG. Analysis and quantification of multiple methylation variable positions in CpG islands by pyrosequencing. Biotechniques. 2003;35:152\u20136.","journal-title":"Biotechniques"},{"key":"293_CR18","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/ng.3889","volume":"49","author":"D Brocks","year":"2017","unstructured":"Brocks D, Schmidt CR, Daskalakis M, Jang HS, Shah NM, Li D, et al. DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. Nat Genet. 2017;49:1052\u201360.","journal-title":"Nat Genet"},{"key":"293_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1868-7083-5-3","volume":"5","author":"M Karahoca","year":"2013","unstructured":"Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2\u2032-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics. 2013;5:3.","journal-title":"Clin Epigenetics"},{"key":"293_CR20","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/cncr.29083","volume":"121","author":"M L\u00fcbbert","year":"2015","unstructured":"L\u00fcbbert M, Kuendgen A. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia\/myelodysplastic syndrome: achievements and challenges. Cancer . 2015;121:498\u2013501.","journal-title":"Cancer"},{"key":"293_CR21","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1093\/nar\/gkt077","volume":"41","author":"K Pandiyan","year":"2013","unstructured":"Pandiyan K, You JS, Yang X, Dai C, Zhou XJ, Baylin SB, et al. Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res. 2013;41:3973\u201385.","journal-title":"Nucleic Acids Res"},{"key":"293_CR22","doi-asserted-by":"crossref","unstructured":"Ramos M-P, Wijetunga NA, McLellan AS, Suzuki M, Greally JM. DNA demethylation by 5-aza-2\u2032-deoxycytidine is imprinted, targeted to euchromatin, and has limited transcriptional consequences. Epigenetics Chromatin. 2015;8:11.","DOI":"10.1186\/s13072-015-0004-x"},{"key":"293_CR23","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1182\/blood-2014-03-562694","volume":"125","author":"T Ueda","year":"2015","unstructured":"Ueda T, Nagamachi A, Takubo K, Yamasaki N, Matsui H, Kanai A, et al. Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2. Blood. 2015;125:3437\u201346.","journal-title":"Blood"},{"key":"293_CR24","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1038\/bcj.2015.37","volume":"5","author":"YS Lai","year":"2015","unstructured":"Lai Y-S, Chen J-Y, Tsai H-J, Chen T-Y, Hung W-C. The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells. Blood Cancer J. 2015;5:e313.","journal-title":"Blood Cancer J"},{"key":"293_CR25","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1038\/sj.onc.1209591","volume":"25","author":"E Reed-Inderbitzin","year":"2006","unstructured":"Reed-Inderbitzin E, Moreno-Miralles I, Vanden-Eynden SK, Xie J, Lutterbach B, Durst-Goodwin KL, et al. RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription. Oncogene. 2006;25:5777\u201386.","journal-title":"Oncogene"},{"key":"293_CR26","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","volume":"72","author":"N Stopa","year":"2015","unstructured":"Stopa N, Krebs JE, Shechter D. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cell Mol Life Sci Cmls. 2015;72:2041\u201359.","journal-title":"Cell Mol Life Sci Cmls"},{"key":"293_CR27","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.18632\/oncotarget.3072","volume":"6","author":"RM Baldwin","year":"2015","unstructured":"Baldwin RM, Haghandish N, Daneshmand M, Amin S, Paris G, Falls TJ, et al. Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression. Oncotarget. 2015;6:3013\u201332.","journal-title":"Oncotarget"},{"key":"293_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.leukres.2010.02.004","volume":"34","author":"M Almstedt","year":"2010","unstructured":"Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, J\u00e4ger E, et al. The DNA demethylating agent 5-aza-2\u2032-deoxycytidine induces expression of NY-ESO-1 and other cancer\/testis antigens in myeloid leukemia cells. Leuk Res. 2010;34:899\u2013905.","journal-title":"Leuk Res"},{"key":"293_CR29","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.bbagrm.2013.08.001","volume":"1829","author":"M Kulis","year":"2013","unstructured":"Kulis M, Queir\u00f3s AC, Beekman R, Mart\u00edn-Subero JI. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim Biophys Acta. 2013;1829:1161\u201374.","journal-title":"Biochim Biophys Acta"},{"key":"293_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1101\/gr.147942.112","volume":"23","author":"KE Varley","year":"2013","unstructured":"Varley KE, Gertz J, Bowling KM, Parker SL, Reddy TE, Pauli-Behn F, et al. Dynamic DNA methylation across diverse human cell lines and tissues. Genome Res. 2013;23:555\u201367.","journal-title":"Genome Res"},{"key":"293_CR31","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood-2012-09-459313","volume":"121","author":"JM Klco","year":"2013","unstructured":"Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V, et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood. 2013;121:1633\u201343.","journal-title":"Blood"},{"key":"293_CR32","doi-asserted-by":"crossref","unstructured":"Lund K, Cole JJ, VanderKraats ND, McBryan T, Pchelintsev NA, Clark W, et al. DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML. Genome Biol. 2014;15:406.","DOI":"10.1186\/s13059-014-0406-2"},{"key":"293_CR33","doi-asserted-by":"publisher","first-page":"40778","DOI":"10.1074\/jbc.M103921200","volume":"276","author":"N Cervoni","year":"2001","unstructured":"Cervoni N, Szyf M. Demethylase activity is directed by histone acetylation. J Biol Chem. 2001;276:40778\u201387.","journal-title":"J Biol Chem"},{"key":"293_CR34","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1097\/CAD.0b013e32835739dd","volume":"23","author":"S Gu","year":"2012","unstructured":"Gu S, Tian Y, Chlenski A, Salwen HR, Lu Z, Raj JU, et al. Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma. Anticancer Drugs. 2012;23:1054\u201366.","journal-title":"Anticancer Drugs"},{"key":"293_CR35","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1182\/blood-2011-02-336891","volume":"118","author":"M Kalac","year":"2011","unstructured":"Kalac M, Scotto L, Marchi E, Amengual J, Seshan VE, Bhagat G, et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. 2011;118:5506\u201316.","journal-title":"Blood"},{"key":"293_CR36","first-page":"961","volume":"62","author":"G Liang","year":"2002","unstructured":"Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2\u2032-deoxycytidine. Cancer Res. 2002;62:961\u20136.","journal-title":"Cancer Res"},{"key":"293_CR37","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ccr.2004.08.029","volume":"6","author":"D Gius","year":"2004","unstructured":"Gius D, Cui H, Bradbury CM, Cook J, Smart DK, Zhao S, et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell. 2004;6:361\u201371.","journal-title":"Cancer Cell"},{"issue":"15 Supplement","key":"293_CR38","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1158\/1538-7445.AM2015-5371","volume":"75","author":"H Falk","year":"2015","unstructured":"Falk H, Foitzik RC, Allan E, deSilva M, Yang H, Bozikis YE, et al. Abstract 5371: PRMT5 inhibitors as novel treatment for cancers. Cancer Res. 2015;75(15 Supplement):5371.","journal-title":"Cancer Res"},{"key":"293_CR39","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.celrep.2015.12.034","volume":"14","author":"V Boom van den","year":"2016","unstructured":"van den Boom V, Maat H, Geugien M, Rodr\u00edguez L\u00f3pez A, Sotoca AM, Jaques J, et al. Non-canonical PRC1.1 targets active genes independent of H3K27me3 and is essential for leukemogenesis. Cell Rep. 2016;14:332\u201346.","journal-title":"Cell Rep"},{"key":"293_CR40","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1182\/blood-2010-10-312736","volume":"117","author":"J He","year":"2011","unstructured":"He J, Nguyen AT, Zhang Y. KDM2b\/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood. 2011;117:3869\u201380.","journal-title":"Blood"},{"key":"293_CR41","doi-asserted-by":"publisher","first-page":"30984","DOI":"10.1074\/jbc.M112.341040","volume":"287","author":"A Janzer","year":"2012","unstructured":"Janzer A, Stamm K, Becker A, Zimmer A, Buettner R, Kirfel J. The H3K4me3 histone demethylase Fbxl10 is a regulator of chemokine expression, cellular morphology, and the metabolome of fibroblasts. J Biol Chem. 2012;287:30984\u201392.","journal-title":"J Biol Chem"},{"key":"293_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1967-5","volume":"15","author":"G Greve","year":"2015","unstructured":"Greve G, Schiffmann I, Pfeifer D, Pantic M, Sch\u00fcler J, L\u00fcbbert M. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells. BMC Cancer. 2015;15:947.","journal-title":"BMC Cancer"},{"key":"293_CR43","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1038\/onc.2011.32","volume":"30","author":"J Duque-Afonso","year":"2011","unstructured":"Duque-Afonso J, Yalcin A, Berg T, Abdelkarim M, Heidenreich O, L\u00fcbbert M. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1\/ETO. Oncogene. 2011;30:3062\u201372.","journal-title":"Oncogene"},{"key":"293_CR44","doi-asserted-by":"crossref","unstructured":"Yao L, Shen H, Laird PW, Farnham PJ, Berman BP. Inferring regulatory element landscapes and transcription factor networks from cancer methylomes. Genome Biol. 2015;16:105.","DOI":"10.1186\/s13059-015-0668-3"},{"key":"293_CR45","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1038\/leu.2012.49","volume":"26","author":"A Ptasinska","year":"2012","unstructured":"Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J, et al. Depletion of RUNX1\/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia. 2012;26:1829\u201341.","journal-title":"Leukemia"},{"key":"293_CR46","doi-asserted-by":"crossref","unstructured":"Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Blagitko-Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7:12840\u201356.","DOI":"10.18632\/oncotarget.7326"},{"key":"293_CR47","doi-asserted-by":"crossref","first-page":"587","DOI":"10.18632\/oncotarget.1782","volume":"5","author":"H Li","year":"2014","unstructured":"Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen R-WC, Vatapalli R, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014;5:587\u201398.","journal-title":"Oncotarget"},{"key":"293_CR48","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume":"28","author":"H Yang","year":"2014","unstructured":"Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng Q-R, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280\u20138.","journal-title":"Leukemia"},{"key":"293_CR49","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/bmt.2009.64","volume":"44","author":"M L\u00fcbbert","year":"2009","unstructured":"L\u00fcbbert M, Bertz H, R\u00fcter B, Marks R, Claus R, W\u00e4sch R, et al. Non-intensive treatment with low-dose 5-aza-2\u2032-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS\/AML patients. Bone Marrow Transplant. 2009;44:585\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"293_CR50","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/bmt.2015.10","volume":"50","author":"J Steinmann","year":"2015","unstructured":"Steinmann J, Bertz H, W\u00e4sch R, Marks R, Zeiser R, Bogatyreva L, et al. 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft. Bone Marrow Transplant. 2015;50:690\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"293_CR51","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1038\/leu.2017.242","volume":"31","author":"G Bug","year":"2017","unstructured":"Bug G, Burchert A, Wagner E-M, Kr\u00f6ger N, Berg T, G\u00fcller S, et al. Phase I\/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). Leukemia. 2017;31:2523\u20135.","journal-title":"Leukemia"},{"key":"293_CR52","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015;162:974\u201386.","journal-title":"Cell"},{"key":"293_CR53","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell 2015;162:961\u201373.","journal-title":"Cell"},{"key":"293_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1432-5","volume":"15","author":"O Grishina","year":"2015","unstructured":"Grishina O, Schmoor C, D\u00f6hner K, Hackanson B, Lubrich B, May AM, et al. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients\u2009>\u200960 years with acute myeloid leukemia who are ineligible for induction chemotherapy. BMC Cancer. 2015;15:430.","journal-title":"BMC Cancer"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0293-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0293-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0293-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:36:07Z","timestamp":1684604167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0293-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["293"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0293-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,23]]},"assertion":[{"value":"15 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}